Intact Investment Management Inc. Purchases 103,600 Shares of Pfizer Inc. (NYSE:PFE)

Intact Investment Management Inc. raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 30.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 438,800 shares of the biopharmaceutical company’s stock after acquiring an additional 103,600 shares during the quarter. Intact Investment Management Inc.’s holdings in Pfizer were worth $12,633,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Addison Advisors LLC increased its holdings in shares of Pfizer by 11.6% during the 4th quarter. Addison Advisors LLC now owns 9,322 shares of the biopharmaceutical company’s stock worth $268,000 after purchasing an additional 970 shares during the period. Gilliland Jeter Wealth Management LLC bought a new stake in Pfizer in the fourth quarter valued at about $962,000. Headlands Technologies LLC bought a new stake in Pfizer in the fourth quarter valued at about $1,184,000. Citizens Financial Group Inc. RI increased its stake in Pfizer by 40.7% in the fourth quarter. Citizens Financial Group Inc. RI now owns 145,969 shares of the biopharmaceutical company’s stock valued at $4,202,000 after acquiring an additional 42,202 shares during the period. Finally, Golden State Equity Partners increased its stake in Pfizer by 134.2% in the fourth quarter. Golden State Equity Partners now owns 25,493 shares of the biopharmaceutical company’s stock valued at $734,000 after acquiring an additional 14,607 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE stock traded up $0.14 during trading hours on Friday, reaching $25.40. 46,526,457 shares of the company were exchanged, compared to its average volume of 34,120,812. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $40.37. The stock’s fifty day moving average is $26.96 and its two-hundred day moving average is $28.42. The company has a market cap of $143.83 billion, a price-to-earnings ratio of 70.56, a P/E/G ratio of 1.14 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.14 earnings per share. Sell-side analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.61%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is 466.67%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on PFE. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Guggenheim began coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.